What is the market doing?
What the tape says about INBX
Inhibrx Biosciences, Inc. is +381% over the past year while the S&P 500 is +20%: 360 points ahead of the market.
+381%
1-year return · S&P 500 +20%
- vs 200-day average
- +30%
vs 200-day average · a clear uptrend
- RSI (14)
- 71
RSI (14) · overbought, bought harder than it has been sold
- Below its 52-week high
- 19%
Below its 52-week high
Details›
- Last close2026-09-08
- $114.78
- 1 monthS&P 500 −0.30%
- +34%
- 1 yearS&P 500 +20%
- +381%
- vs 50-day average$96.82
- +19%
- 52-week high
- $141.84
- 52-week low
- $23.00
- Annualised volatility
- 100%
| Year | Return |
|---|---|
| 2026 (year to date) | +45% |
| 2025 | +413% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 2 | 0 of 2 | −7.6% |
| Feb | 2 | 0 of 2 | −2.6% |
| Mar | 2 | 1 of 2 | −1.9% |
| Apr | 2 | 1 of 2 | +40% |
| May | 2 | 1 of 2 | −5.1% |
| Jun | 3 | 1 of 3 | −5.1% |
| Jul | 3 | 2 of 3 | +13% |
| Aug | 3 | 3 of 3 | +29% |
| Sep | 3 | 2 of 3 | +5.9% |
| Oct | 2 | 2 of 2 | +72% |
| Nov | 2 | 1 of 2 | −0.90% |
| Dec | 2 | 1 of 2 | −2.6% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.